Advice
Following a full submission
darifenacin (Emselex®) is accepted for restricted use within NHS Scotland for the symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.
Darifenacin is effective in reducing symptoms associated with overactive bladder, including frequency, urgency and incontinence and the treatment effect is similar to another antimuscarinic. Darifenacin is associated with adverse effects typical of antimuscarinic agents used in this condition. It is restricted to second line use as there are cheaper antimuscarinics available that would normally be used as first-line agents.
Download detailed advice101KB (PDF)
Medicine details
- Medicine name:
- darifenacin 7.5 mg, 15 mg prolonged-release tablets(Emselex)
- SMC ID:
- 377/07
- Indication:
- Urge incontinence
- Pharmaceutical company
- Ardana Bioscience
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 11 June 2007